PRKN and neoplasm: Not surprisingly, further investigation showed PARK2 was a tumor suppressor in ESCC from clinical aspects, while the molecular mechanisms revealed a novel regulatory manner: PARK2 modulated Hippo pathway by promoting YAP protein ubiquitination and degradation in ESCC cells.